Small molecule · Inhibitor of vascular endothelial growth factor receptor 3 (FLT4) · developed by Kazia Therapeutics
EVT801 is an orally bioavailable small molecule that binds and inhibits the tyrosine kinase of VEGFR3 (FLT4), a receptor expressed on lymphatic endothelial cells and in many solid and hematologic malignancies. By blocking VEGFR3 it is intended to inhibit tumor angiogenesis and may also reduce circulating myeloid-derived suppressor cells. It is being studied in adult patients with solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05114668 | Phase 1 | Solid Tumor, Adult | Completed | KZIA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor, Adult
Updated Oct 18, 2026. Something wrong or missing? Report it on the KZIA page.
See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KZIA catalysts and pipeline →